Announced Wed, 7 Oct, 2026 · 18:44 IST

Beryl Drugs files non applicability certificate under Reg 57(5) for Sep 2026 quarter

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹25.55

prior close

₹24.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.8%+1.6% vs market

Pharmaceuticals peers, median of 172sector-2.5%+1.3% vs sector

On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+13.9

10m

+12.0

15m

+12.0

30m

+12.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-2.8+1.6-2.5+1.3

Next day

+3.3-2.5+5.8-2.6+5.9

-0.2-1.7+1.4-2.5+2.3

-2.2-1.5-0.7-2.6+0.4

-4.1-0.8-3.3-2.5-1.6

-8.5-2.4-6.1-3.2-5.4

-2.6-3.4+0.8-4.4+1.8

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beryl Drugs Ltd has submitted a Non-Applicability Certificate under SEBI Regulation 57(5) for the quarter ended 30 September 2026. The company stated that the regulation does not apply as it has no non-convertible securities requiring interest, dividend, or principal payments during the quarter. A Regulation 74(5) certificate relating to depository participants was also filed alongside.

Likely market impact

Routine compliance filing with no material impact on shareholders or stock price. Company simply has no NCDs or similar instruments outstanding.